Geode Capital Management LLC Has $186.85 Million Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Geode Capital Management LLC increased its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 0.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 7,312,551 shares of the biopharmaceutical company’s stock after purchasing an additional 46,765 shares during the quarter. Geode Capital Management LLC’s holdings in Royalty Pharma were worth $186,846,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Keene & Associates Inc. increased its position in shares of Royalty Pharma by 1.9% during the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock worth $495,000 after acquiring an additional 370 shares in the last quarter. National Bank of Canada FI boosted its stake in Royalty Pharma by 21.8% in the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 371 shares during the period. Blue Trust Inc. increased its holdings in Royalty Pharma by 31.3% during the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 376 shares in the last quarter. Sanctuary Advisors LLC raised its stake in shares of Royalty Pharma by 0.9% in the 4th quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company’s stock valued at $1,068,000 after purchasing an additional 388 shares during the period. Finally, Arizona State Retirement System lifted its holdings in shares of Royalty Pharma by 0.5% in the fourth quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company’s stock valued at $2,822,000 after purchasing an additional 537 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on RPRX. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. Citigroup reiterated a “buy” rating on shares of Royalty Pharma in a research note on Friday, March 28th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $41.60.

Royalty Pharma Price Performance

NASDAQ:RPRX opened at $31.11 on Monday. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20. The firm has a market capitalization of $17.93 billion, a price-to-earnings ratio of 21.46, a P/E/G ratio of 2.31 and a beta of 0.50. The stock’s 50 day moving average price is $32.52 and its two-hundred day moving average price is $28.97. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, analysts anticipate that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.83%. The ex-dividend date was Friday, February 21st. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio (DPR) is currently 60.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.